INS and metabolic dysfunction-associated steatotic liver disease: Potential actions may be the regulation of hepatic gene expression, the improvement of insulin sensitivity, and the reduction of inflammation and of oxidative stress.142 The WELCOME Trial tested the effects of the regular ingestion of 4 g of eicosapentaenoic acid plus docosahexaenoic acid (approved for treatment of hypertriglyceridemia),143 and showed an improvement of NAFLD.144 However, other trials have been overall negative.145,146 It is also possible that particular PUFAs may be more beneficial than others.